Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?
Zucker
Stanley
S
Veterans Affairs Medical Center, Northport, NY, USA. stanley.zucker@va.gov
Cao
Jian
J
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D002986:Clinical Trials as Topic; D019281:Dimerization; D018450:Disease Progression; D005109:Extracellular Matrix / Q000378:metabolism; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D051379:Mice; D008954:Models, Biological; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*
D000970:Antineoplastic Agents; D061965:Matrix Metalloproteinase Inhibitors